Business Wire

PHARNEXT-SA

Del

Pharnext to Present at 2017 BIO CEO & Investor Conference

Regulatory News:

Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that company management will present a corporate overview at the 2017 BIO CEO & Investor Conference.

The presentation will take place as follows:

  • Date : Monday, February 13th , 2017
  • Time: 10:00 am ET (4:00 pm CET)
  • Venue : The Waldorf Astoria in New York, New York.

If you are interested in meeting the Pharnext management team during this event, please send an email to Sarah McCabe at sarah@sternir.com

About Pharnext

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY . The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit www.pharnext.com

Contact:

Pharnext
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
investors@pharnext.com
or
Investors Relations (Europe)
Anne Hennecke, +49 211 529252 22
MC Services AG
anne.hennecke@mc-services.eu
or
Investors Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1 212-362-1200
sarah@sternir.com
or
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol
Margaux Pronost
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Media Relations (U.S.)
Russo Partners
Tony Russo, Ph.D., +1 212-845-4251
tony.russo@russopartnersllc.com
or
Victoria Meissner, M.D., +1 646-942-5627
victoria.meissner@russopartnersllc.com
or
Financial Communication (France)
NewCap
Julie Coulot, +33 (0)1 44 71 20 40
pharnext@newcap.eu

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com